Publications:492
Video Visit Available
Accepting New Patients
- Mount Sinai Doctors
- Treats Adults
- Video Visit Available
- Accepting New Patients
Matthew Galsky, MD
Cancer (Oncology)
About Me
Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Deputy Director of the Mount Sinai Tisch Cancer Center (a NCI-Designated Comprehensive Cancer Center), Director of Genitourinary Medical Oncology, and Co-Director of the Center of Excellence for Bladder Cancer at the Mount Sinai Tisch Cancer Center. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Language
English
Position
PROFESSOR | Medicine, Hematology and Medical Oncology, PROFESSOR | Urology
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
Clinical Focus
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Cancer
- Testicular Tumors
- Urologic Cancers
Video
Education
MD, Tufts University
Residency, Internal Medicine
Beth Israel Deaconess Medical Center
Fellowship, Medical Oncology
Memorial Sloan-Kettering Cancer Center
Certifications
American Board of Internal Medicine
Awards
2003
American Society of Clinical Oncology Merit Award
1998
Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)
1998
Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
1997
Alpha Omega Alpha Honor Society
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information. Patients with Anthem Blue Cross Blue Shield (formerly known as Empire) please click here for more information. Patients with Molina insurance should click here for more information. Mount Sinai’s contracts with Anthem and Molina expired on December 31.
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oscar
- Oxford - Freedom and Liberty
- United Health Care - Commercial
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial. J. Bedke, M. S. van der Heijden, G. Sonpavde, M. D. Galsky, W. Liao, L. Shi, S. I. Blum, S. Mitra, M. Y. Patel, T. Powles. ESMO Open
- Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. Karine Tawagi, Ali R. Khaki, Priyanka V. Chablani, Jeannie Hoffman-Censits, Vadim S. Koshkin, Elizabeth R. Plimack, Matt D. Galsky, Shilpa Gupta, Jonathan E. Rosenberg, Petros Grivas, Peter H. O’Donnell. Clinical Genitourinary Cancer
- Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer. Matthew D. Galsky, Sudeh Izadmehr, Menggang Yu, Samuel D. Curtis, Christopher Douville, Maria Popoli, Janine Ptak, Lisa Dobbyn, Natalie Silliman, Kevin G. Chan, Tanya B. Dorff, Jeremy P. Cetnar, Brock O’Neil, Anishka D’Souza, Ronac Mamtani, Christos E. Kyriakopoulos, Rachel Brody, Evita Sadimin, Reza Mehrazin, Diego Chowell, John Sfakianos, Siamak Daneshmand, Sumanta K. Pal, Chetan Bettegowda, Kenneth W. Kinzler, Nickolas Papadopoulos, Bert Vogelstein, Yuxuan Wang. Proceedings of the National Academy of Sciences of the United States of America
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Galsky during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Aktis
- Merck & Co., Inc.
- AbbVie, Inc.
- AstraZeneca
- Seattle Genetics
- Gilead Sciences
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.